Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 4/20 | 0.65 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 3/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 6/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322058 | 1.00 | PTK2 (0.65) | PTK2PTK2BAURKAAURKBLRRK2 | |
| SCHEMBL578552 | 0.93 | PTK2 (0.69) | PTK2PTK2BAURKAAURKBLRRK2 | |
| SCHEMBL578551 | 0.93 | PTK2 (0.69) | PTK2PTK2BAURKAAURKBLRRK2 | |
| SCHEMBL2322143 | 0.90 | PTK2 (0.65) | PTK2PTK2BAURKAAURKBKIT | |
| SCHEMBL2322148 | 0.90 | PTK2 (0.65) | PTK2PTK2BAURKAAURKBKIT | |
| SCHEMBL12236309 | 0.89 | CDK1 (0.54) | PTK2PTK2BLRRK2CDK1CDK2 | |
| SCHEMBL12235235 | 0.89 | PTK2 (0.52) | PTK2PTK2BAURKAAURKBKIT | |
| SCHEMBL5576448 | 0.89 | PTK2 (0.53) | PTK2PTK2BAURKAKITFLT3 | |
| SCHEMBL12235658 | 0.89 | PTK2 (0.53) | PTK2PTK2BAURKAKITFLT3 | |
| SCHEMBL4189858 | 0.89 | PTK2 (0.53) | PTK2PTK2BAURKAKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | claimed |
| EP-2357181-A1 | 2,4-Diaminopyrimidines as inhibitors of cell cycle kinases | Boehringer Ingelheim International GmbH (DE) | 2011-08-17 | — | — | EP | claimed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | claimed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2357181-A1 | 2,4-Diaminopyrimidines as inhibitors of cell cycle kinases | Boehringer Ingelheim International GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163467-A1 | New compounds | CCNA1, MKI67, CCNT1 | PTK2 1550/4885PTK2B 2309/4885AURKA 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.